Lulizumab pegol

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameLulizumab pegol
Drug Alias NameBMS-931699Lulizumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 modulatorsImmunosuppressants
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsRejection of renal transplantationSjogren-Larsson SyndromeLupus Vulgaris
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyNational Institute Of Allergy And Infectious Diseases (Niaid)
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsSjogren-Larsson SyndromeLupus Vulgaris

Other Information

ATC CodeN/A
Related LinksWikipedia